NexImmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEXI research report →
Range $2 – $5
Price Chart
About the company
NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform.
- CEO
- Craig R. Jalbert
- IPO
- 2021
- Employees
- 6
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on NEXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $139
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -180.64%
- ROIC
- -815.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,024,972+31.5%
- Op Income
- $-29,192,480
- Net Income
- $-32,344,392-106.3%
- EPS
- $-30.82-105.8%
- OCF Growth
- +38.6%
- FCF Growth
- +40.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 4.05
- RSI (14)
- 48
- Avg Volume
- 16
No earnings-call transcripts are available for NEXI yet.
- Free Float
- 84.5%
- Shares Outstanding
- 1.39M
- Float Shares
- 1.18M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Raymond James & Associates | 10.80K | 0 |
Held by 26 ETFs
Biggest fund positions in NEXI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 24 | Jones Kristi | buy | 1 |
| Apr 5, 24 | Marchio Albert N II | other | 0 |
| Nov 21, 23 | Roemer Alan S. | sell | 3,833 |
| Nov 22, 23 | Roemer Alan S. | sell | 3,992 |
| Aug 30, 23 | STOVER TIMOTHY | other | 0 |
| Aug 30, 23 | STOVER TIMOTHY | other | 11,625 |
| Aug 30, 23 | STOVER TIMOTHY | other | 6,375 |
| Jul 5, 23 | Verstandig Grant | other | 44,983 |
| Jul 5, 23 | Gandhi Leena | other | 44,983 |
| Jul 5, 23 | Yao Zhengbin | other | 44,983 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NEXI coverage
Recent articles, reports, and earnings notes.
No research on NEXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEXI report →Italian state investor CDP to raise stake in payments group Nexi
reuters.com · May 25
Italy's CDP against selling stake in Nexi, sources say
reuters.com · Apr 29
Graybug Vision (NASDAQ:GRAY) versus NexImmune (OTCMKTS:NEXI) Head-To-Head Review
defenseworld.net · Feb 20
NexImmune (NASDAQ:NEXI) Stock Price Up 2,169,900% – Here’s Why
defenseworld.net · Dec 31
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
defenseworld.net · Dec 25
Critical Comparison: NexImmune (NASDAQ:NEXI) vs. IMV (OTCMKTS:IMVIQ)
defenseworld.net · Dec 10
Critical Survey: NexImmune (NASDAQ:NEXI) and Palatin Technologies (PINK:PTNT)
defenseworld.net · Dec 10
Head-To-Head Survey: NexImmune (NASDAQ:NEXI) versus Evotec (OTCMKTS:EVTCY)
defenseworld.net · Nov 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.